IP Library Granted Patent US 9,763,998
Granted Patent B2
US 9,763,998 · App. 14/186,054 · Granted Sep 19, 2017

Serpins: methods of therapeutic β-cell regeneration and function

Inventors: Rohit N. Kulkarni (Chestnut Hill, MA); Abdelfattah El Ouaamari (Boston, MA); Daniel Margerie (Frankfurt am Main, DE); Matthias Lohmann (Frankfurt am Main, DE); Jean Claude Guillemot (Espanes, FR); Denis Loyaux (Belbeze, FR)
Assignee: Joslin Diabetes Center, Inc.
A61K38/1709A61K38/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,763,998
App. No.
14/186,054
Granted
Sep 19, 2017
Kind
B2
Abstract

Compositions and methods of use are provided for improving β cell function and promoting pancreatic β cell proliferation in vitro, in vivo and ex vivo. The active agents of the pending invention comprise Serpin family peptides (e.g., SerpinB1), functional and structural analogs of Serpin family peptides and nucleic acids encoding Serpin family peptides, as well as active fragments thereof.

Claims (8)

1. A method of promoting pancreatic β cell proliferation in vitro, said method comprising:

contacting a population of human pancreatic β cells with an isolated SerpinB1 protein thereby promoting pancreatic β cell proliferation.

2. A method of promoting pancreatic β cell proliferation in vivo comprising administering a SerpinB1 protein in a pharmacological carrier to a subject in need thereof, thereby promoting pancreatic β cell proliferation in the subject.

3. The method of claim 2 , wherein the subject has impaired glucose tolerance.

4. The method of claim 3 , wherein administering said SerpinB1 protein to said subject with impaired glucose tolerance improves glycemic control or improves insulin sensitivity.

5. The method of claim 2 , wherein the subject is at risk of developing diabetes.

6. The method of claim 2 , wherein the subject suffers from type 1 or type 2 diabetes.

7. The method of claim 2 , further comprising detecting glycemic control in the subject, wherein an increase in glycemic control indicates pancreatic β cell proliferation in vivo.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2016
From: KULKARNI, ROHIT N.; EL OUAAMARI, ABDELFATTAH
To: JOSLIN DIABETES CENTER, INC.
Reel/Frame 039405/0246 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2016
From: MARGERIE, DANIEL; LOHMANN, MATTHIAS; GUILLEMOT, JEAN CLAUDE; LOYAUX, DENIS
To: SANOFI
Reel/Frame 039215/0136 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2016
From: SANOFI
To: JOSLIN DIABETES CENTER
Reel/Frame 039215/0170 →
CONFIRMATORY LICENSE Recorded Jun 20, 2016
From: JOSLIN DIABETES CENTER
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039080/0116 →
Priority Claims (1)
EP 13305204 · Feb 22, 2013 · regional
Continuity (2)
Provisional Application 61767948 · Feb 22, 2013
Related Publication 20150366940A1 · Dec 24, 2015